This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Lipella Pharmaceuticals’s 8K filing here.
About Lipella Pharmaceuticals
Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).
Further Reading
- Five stocks we like better than Lipella Pharmaceuticals
- Stock Dividend Cuts Happen Are You Ready?
- 3 Must-Hold Stocks with Double-Digit Upside for 2025
- Market Cap Calculator: How to Calculate Market Cap
- Micron: Why Now Is the Time to Be Brave
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
